Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.71 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | ESRRB | O95718 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ESRRA | P11474 | 1/20 | 0.49 |
| ▸ | ESRRG | P62508 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | CKS1B | P61024 | 1/20 | 0.49 |
| ▸ | SKP1 | P63208 | 1/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1481563 | 0.95 | GPR119 (0.78) | GPR119MAPTKMT2AALDH1A1LMNA | |
| SCHEMBL64850 | 0.87 | SMN1; SMN2 (0.57) | GPR119MAPTKMT2AALDH1A1LMNA | |
| SCHEMBL13281422 | 0.86 | MAPT (0.62) | GPR119MAPTKMT2AALDH1A1LMNA | |
| SCHEMBL5231173 | 0.86 | GPR119 (0.70) | GPR119MAPTKMT2AALDH1A1LMNA | |
| SCHEMBL21750394 | 0.86 | MAPT (0.56) | GPR119MAPTKMT2AALDH1A1LMNA | |
| SCHEMBL5231126 | 0.86 | MAPT (0.56) | GPR119MAPTKMT2AALDH1A1LMNA | |
| SCHEMBL5573222 | 0.86 | MAPT (0.76) | GPR119MAPTKMT2AALDH1A1LMNA | |
| SCHEMBL5236861 | 0.85 | MAPT (0.61) | GPR119MAPTKMT2AALDH1A1LMNA | |
| SCHEMBL411201 | 0.85 | MAPT (0.61) | GPR119MAPTKMT2AALDH1A1LMNA | |
| SCHEMBL5230610 | 0.85 | ALDH1A1 (0.61) | GPR119MAPTKMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219234-A1 | Thienopyridine Derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1764367-A1 | THIENOPYRIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
| US-6849631-B2 | Semicarbazides and their uses | BRISTOL MYERS SQUIBB PHARMA COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1351956-A1 | SEMICARBAZIDES AND THEIR USES AS CYCLIN DEPENDENT KINASE INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20020091127-A1 | Semicarbazides and their uses | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-11 | — | — | US | disclosed |
| US-6407103-B2 | POTENT ENZYME INHIBITORS OF CYCLIN-DEPENDENT KINASES RELATING TO THE CATALYTIC SUBUNITS CDK1-9 AND THEIR REGULATORY SUBUNITS CYCLINS A-H; ANTIPROLIFERATIVE, -CARCINOGENIC AND -TUMOR AGENTS; VIRICIDES; MODULATORS OF DNA/RNA BIOSYNTHESIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-18 | — | — | US | disclosed |
| WO-2002046182-A1 | SEMICARBAZIDES AND THEIR USES AS CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| US-20010027195-A1 | Indeno [1,2-c]pyrazol-4-ones and their uses | DUPONT PHARMACEUTICALS COMPANY | 2001-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027195-A1 | Indeno [1,2-c]pyrazol-4-ones and their uses | CDK1, CCNA1, CDK19 | GPR119 2038/4885MAPT 4275/4885KMT2A 1836/4885 |
| US-20070219234-A1 | Thienopyridine Derivatives | RASGRP1, NRAS, HRH3 | GPR119 558/4885MAPT 4452/4885KMT2A 2660/4885 |
| US-20020091127-A1 | Semicarbazides and their uses | CDK1, CCNA1, CDK17 | GPR119 1896/4885MAPT 4673/4885KMT2A 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.